THRB and metabolic dysfunction-associated steatohepatitis: Recently, the Food and Drug Administration (FDA) approved resmetirom, an oral thyroid hormone receptor-beta (THRβ) agonist, as a treatment for adult patients with NASH and associated fibrosis [4].